Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Brief Summary: This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.


Options:
A: Arm Label: Atezolizumab + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Bevacizumab | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Assigned to Arm(s): Atezolizumab + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab + Bevacizumab | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
B: Arm Label: Arm I (sunitinib malate); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Procedure: Computed Tomography, Drug: Sunitinib Malate | Arm Label: Arm II (cabozantinib s-malate); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Drug: Cabozantinib S-malate, Procedure: Computed Tomography | Arm Label: Arm III (crizotinib closed to accrual 12/5/18); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Procedure: Computed Tomography, Drug: Crizotinib | Arm Label: Arm IV (savolitinib closed to accrual 12/5/18); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Scan, Procedure: Computed Tomography, Drug: Savolitinib | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm I (sunitinib malate), Arm II (cabozantinib s-malate), Arm III (crizotinib closed to accrual 12/5/18), Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: PROCEDURE; Name: Bone Scan; Assigned to Arm(s): Arm I (sunitinib malate), Arm II (cabozantinib s-malate), Arm III (crizotinib closed to accrual 12/5/18), Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Cabozantinib S-malate; Assigned to Arm(s): Arm II (cabozantinib s-malate) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (sunitinib malate), Arm II (cabozantinib s-malate), Arm III (crizotinib closed to accrual 12/5/18), Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Crizotinib; Assigned to Arm(s): Arm III (crizotinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Savolitinib; Assigned to Arm(s): Arm IV (savolitinib closed to accrual 12/5/18) | Intervention Type: DRUG; Name: Sunitinib Malate; Assigned to Arm(s): Arm I (sunitinib malate)
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib, Drug: AMG 386 placebo IV | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: AMG 386 placebo IV | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 placebo IV; Assigned to Arm(s): Arm A, Arm C
D: Arm Label: Alternating regimen; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Everolimus | Arm Label: Sequential treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pazopanib, Drug: Everolimus | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen

Answer: A